Amarin Corp Plc (AMRN)

[GCvascEPA2016]

Your experience was consistent with the first successful case of using VASCEPA to treat a COVID-19 patient reported in 2020. Vascepa helped a mother to recover much faster than her daughter (~ 30 years younger) who declined Vascepa.

Cross our fingers for positive PREPARE-IT 2 study results!

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532870/

A 53-year-old woman (Patient #1) with hyperlipidemia and no other known medical conditions presented to the clinic after confirmed exposure as well as a positive test for COVID-19. Her 21-year-old healthy daughter (Patient #2) was similarly exposed at the same time. Both women were of good health, had no other known risk factors for COVID-19, and had a body mass index (BMI) of 21 and 17, respectively. They had not shown any symptoms and received no treatment until the fourth post-exposure day. Four days after being exposed to a confirmed COVID-19 case, both developed persistent fevers up to 101F and later sore throat, nasal congestion, and cough on symptom day (SD) 2 and anosmia on SD4. On SD2, after obtainment of informed consent, Patient #1 began a course of oral IPE (2g twice daily). This treatment was offered to her following our success with this regimen in patients with inflammatory response and shock (report under review for publication). Her daughter (Patient #2) declined IPE. They otherwise received only symptomatic care that did not differ between the two.

Fevers began to subside on SD2, however, symptoms persisted; on SD4, the 53-year-old patient no longer reported any symptoms outside of anosmia, which has later resolved on SD7, five days after beginning treatment with IPE. In comparison, her 21-year-old daughter continued to experience sore throat, nasal congestion, and anosmia through SD18. She had only started experiencing partial relief on SD18, significantly after the complete resolution of symptoms in her mother (see red vertical lines in Figure ?Figure1).1). Figure ?Figure11 displays the course of disease in both patients and emphasizes the difference in disease development with and without IPE treatment.